Dolan Basak

Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial

Simon Parkinson Bach, David Sebag-Montefiore, Victoria Homer, Alexandra Gilbert et autres

BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ …

gb, nl, se, dk, be, us (code pays fourni par la source)

Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial

Martin John Connor, Taimur Tariq Shah, Johanna Sukumar, Dolan Basak et autres

BACKGROUND AND OBJECTIVE: Cytoreduction of the primary prostate cancer, involved lymph nodes, and metastases may confer improved cancer control in de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC). Herein, we aimed to examine the safety and feasibility of novel cytoreductive therapies. METHODS: …

gb (code pays fourni par la source)

PD13-11 ADDITIONAL NOVEL CYTOREDUCTIVE TREATMENTS TO THE PRIMARY TUMOUR AND METASTASIS FOR DE NOVO METASTATIC-HORMONE SENSITIVE PROSTATE CANCER (IP2-ATLANTA): THE INTERNAL PILOT OUTCOMES OF A PHASE II, MULTICENTRE, RANDOMISED CONTROLLED TRIAL

Martin John Connor, Taimur Tariq Shah, Johanna Sukumar, Dolan Basak et autres

IP26-35 NOVEL CYTOREDUCTIVE PROSTATE ABLATIVE THERAPIES IN DE NOVO METASTATIC PROSTATE CANCER: LESSONS LEARNT FROM A PHASE II INTERNAL PILOT RANDOMISED STUDY (IP2-ATLANTA)

Martin John Connor, Taimur Tariq Shah, Johanna Sukumar, Dolan Basak et autres

A0831 – Novel cytoreductive prostate ablative therapies in de novo metastatic prostate cancer: Lessons learnt from a phase II randomised study (IP2-ATLANTA)

M.J. Connor, T. Shah, Johanna Sukumar, Dolan Basak et autres

A0832 – Additional novel cytoreductive treatments to the primary tumour and metastasis for de novo metastatic-hormone sensitive prostate cancer (IP2-ATLANTA): The internal pilot outcomes of a phase II, multicentre, randomised controlled trial

M.J. Connor, T. Shah, Johanna Sukumar, Dolan Basak et autres

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or enhancer region.

gb, it (code pays fourni par la source)

Outcomes of Salvage Radiotherapy and Chemotherapy for Vaginal Vault Carcinoma Following Earlier Hysterectomy

Sultan Pradhan, Abhishek Shinghal, Jhansi Pattanaik, Prashanth Giridhar et autres

in (code pays fourni par la source)

UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228)

P. Kyle, Kitrick Perry, Anne Moutadjer, Nicholas Gilfillan et autres

Objectives: This is the first UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for colorectal cancer peritoneal metastases. This trial aimed to assess the impact of PIPAC in combination with standard of care systemic treatment on: progression free survival (PFS); quality of …

gb (code pays fourni par la source)

A prospective case series assessing the Imperial College London intraoperative radiotherapy protocol for advanced rectal cancer: an IDEAL phase 2a study

Jamie Murphy, Daniella Donato‐Brown, Ouvefe Efeotor, Nicholas Gilfillan et autres

AIM: Intraoperative radiotherapy (IORT) decreases local recurrence rates for advanced rectal cancer. Nevertheless, utilization of IORT is limited due to the associated logistical and financial challenges. The aim of this study is to describe the development and delivery of a novel IORT …

gb (code pays fourni par la source)

Single-centre experience with intensity-modulated radiotherapy for anal cancer: A retrospective analysis

Ragu Prakash Ratnakumara, Rishie Ramkissoon, Dolan Basak, Paul Ziprin et autres

Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study

Martin John Connor, Mesfin G. Genie, Michael Gonzalez, Naveed Sarwar et autres

INTRODUCTION: synchronous metastatic hormone-sensitive prostate cancer (mHSPC). Novel local cytoreductive treatments and metastasis-directed therapy are now being evaluated. Such interventions may provide added survival benefit or delay the requirement for further systemic agents and associated toxicity but can confer additional harm. Understanding …

gb, it (code pays fourni par la source)